Literature DB >> 21994454

Complement-dependent lysis of influenza a virus-infected cells by broadly cross-reactive human monoclonal antibodies.

Masanori Terajima1, John Cruz, Mary Dawn T Co, Jane-Hwei Lee, Kaval Kaur, Jens Wrammert, Patrick C Wilson, Francis A Ennis.   

Abstract

We characterized human monoclonal antibodies (MAbs) cloned from influenza virus-infected patients and from influenza vaccine recipients by complement-dependent lysis (CDL) assay. Most MAbs active in CDL were neutralizing, but not all neutralizing MAbs can mediate CDL. Two of the three stalk-specific neutralizing MAbs tested were able to mediate CDL and were more cross-reactive to temporally distant H1N1 strains than the conventional hemagglutination-inhibiting and neutralizing MAbs. One of the stalk-specific MAbs was subtype cross-reactive to H1 and H2 hemagglutinins, suggesting a role for stalk-specific antibodies in protection against influenza illness, especially by a novel viral subtype which can cause pandemics.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21994454      PMCID: PMC3233150          DOI: 10.1128/JVI.05193-11

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  22 in total

1.  A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains.

Authors:  Y Okuno; Y Isegawa; F Sasao; S Ueda
Journal:  J Virol       Date:  1993-05       Impact factor: 5.103

2.  Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine.

Authors:  Davide Corti; Amorsolo L Suguitan; Debora Pinna; Chiara Silacci; Blanca M Fernandez-Rodriguez; Fabrizia Vanzetta; Celia Santos; Catherine J Luke; Fernando J Torres-Velez; Nigel J Temperton; Robin A Weiss; Federica Sallusto; Kanta Subbarao; Antonio Lanzavecchia
Journal:  J Clin Invest       Date:  2010-04-12       Impact factor: 14.808

3.  Influenza virus M2 protein is an integral membrane protein expressed on the infected-cell surface.

Authors:  R A Lamb; S L Zebedee; C D Richardson
Journal:  Cell       Date:  1985-03       Impact factor: 41.582

4.  Human antibodies reveal a protective epitope that is highly conserved among human and nonhuman influenza A viruses.

Authors:  Andres G Grandea; Ole A Olsen; Thomas C Cox; Mark Renshaw; Philip W Hammond; Po-Ying Chan-Hui; Jennifer L Mitcham; Witold Cieplak; Shaun M Stewart; Michael L Grantham; Andrew Pekosz; Maki Kiso; Kyoko Shinya; Masato Hatta; Yoshihiro Kawaoka; Matthew Moyle
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-01       Impact factor: 11.205

5.  Influenza virus vaccine based on the conserved hemagglutinin stalk domain.

Authors:  John Steel; Anice C Lowen; Taia T Wang; Mark Yondola; Qinshan Gao; Kester Haye; Adolfo García-Sastre; Peter Palese
Journal:  MBio       Date:  2010-05-18       Impact factor: 7.867

6.  Rapid cloning of high-affinity human monoclonal antibodies against influenza virus.

Authors:  Jens Wrammert; Kenneth Smith; Joe Miller; William A Langley; Kenneth Kokko; Christian Larsen; Nai-Ying Zheng; Israel Mays; Lori Garman; Christina Helms; Judith James; Gillian M Air; J Donald Capra; Rafi Ahmed; Patrick C Wilson
Journal:  Nature       Date:  2008-04-30       Impact factor: 49.962

7.  Cytotoxic lymphocytes and antibody-dependent complement-mediated cytotoxicity induced by administration of influenza vaccine.

Authors:  G V Quinnan; F A Ennis; C U Tuazon; M A Wells; G M Butchko; R Armstrong; C McLaren; J F Manischewitz; S Kiley
Journal:  Infect Immun       Date:  1980-11       Impact factor: 3.441

8.  Microneutralization test for influenza A and B and parainfluenza 1 and 2 viruses that uses continuous cell lines and fresh serum enhancement.

Authors:  A L Frank; J Puck; B J Hughes; T R Cate
Journal:  J Clin Microbiol       Date:  1980-09       Impact factor: 5.948

9.  Antibody recognition of a highly conserved influenza virus epitope.

Authors:  Damian C Ekiert; Gira Bhabha; Marc-André Elsliger; Robert H E Friesen; Mandy Jongeneelen; Mark Throsby; Jaap Goudsmit; Ian A Wilson
Journal:  Science       Date:  2009-02-26       Impact factor: 47.728

10.  Hemagglutinin-specific complement-dependent cytolytic antibody response to influenza infection.

Authors:  M W Verbonitz; F A Ennis; J T Hicks; P Albrecht
Journal:  J Exp Med       Date:  1978-01-01       Impact factor: 14.307

View more
  63 in total

1.  Universal influenza virus vaccines: need for clinical trials.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Immunol       Date:  2014-01       Impact factor: 25.606

2.  Comparison of complement dependent lytic, hemagglutination inhibition and microneutralization antibody responses in influenza vaccinated individuals.

Authors:  Mary Dawn T Co; John Cruz; Akira Takeda; Francis A Ennis; Masanori Terajima
Journal:  Hum Vaccin Immunother       Date:  2012-08-16       Impact factor: 3.452

Review 3.  The evolution of seasonal influenza viruses.

Authors:  Velislava N Petrova; Colin A Russell
Journal:  Nat Rev Microbiol       Date:  2017-10-30       Impact factor: 60.633

4.  A Recombinant Rabies Virus Expressing the Marburg Virus Glycoprotein Is Dependent upon Antibody-Mediated Cellular Cytotoxicity for Protection against Marburg Virus Disease in a Murine Model.

Authors:  Rohan Keshwara; Katie R Hagen; Tiago Abreu-Mota; Amy B Papaneri; David Liu; Christoph Wirblich; Reed F Johnson; Matthias J Schnell
Journal:  J Virol       Date:  2019-03-05       Impact factor: 5.103

Review 5.  Advances in the development of influenza virus vaccines.

Authors:  Florian Krammer; Peter Palese
Journal:  Nat Rev Drug Discov       Date:  2015-03       Impact factor: 84.694

6.  Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.

Authors:  Weina Sun; Ericka Kirkpatrick; Megan Ermler; Raffael Nachbagauer; Felix Broecker; Florian Krammer; Peter Palese
Journal:  J Virol       Date:  2019-05-29       Impact factor: 5.103

7.  Diversity of the murine antibody response targeting influenza A(H1N1pdm09) hemagglutinin.

Authors:  Jason R Wilson; Wen-Pin Tzeng; April Spesock; Nedzad Music; Zhu Guo; Robert Barrington; James Stevens; Ruben O Donis; Jacqueline M Katz; Ian A York
Journal:  Virology       Date:  2014-05-10       Impact factor: 3.616

8.  Relationship of preexisting influenza hemagglutination inhibition, complement-dependent lytic, and antibody-dependent cellular cytotoxicity antibodies to the development of clinical illness in a prospective study of A(H1N1)pdm09 Influenza in children.

Authors:  Mary Dawn T Co; Masanori Terajima; Stephen J Thomas; Richard G Jarman; Kamonthip Rungrojcharoenkit; Stefan Fernandez; In-Kyu Yoon; Darunee Buddhari; John Cruz; Francis A Ennis
Journal:  Viral Immunol       Date:  2014-08-20       Impact factor: 2.257

9.  Simultaneous Targeting of Multiple Hemagglutinins to APCs for Induction of Broad Immunity against Influenza.

Authors:  Ane Marie Anderson; Marta Baranowska-Hustad; Ranveig Braathen; Gunnveig Grodeland; Bjarne Bogen
Journal:  J Immunol       Date:  2018-02-02       Impact factor: 5.422

10.  Immunological considerations for developing antibody therapeutics for Influenza A.

Authors:  Po-Ying Chan-Hui; Kristine M Swiderek
Journal:  Hum Vaccin Immunother       Date:  2016       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.